LG Life Sciences' 2nd Quarter Sales Dampened By Strong Won, Tightened Regulatory Watch On Pharma
This article was originally published in PharmAsia News
Executive Summary
SEOUL - The ongoing appreciation of the Korean won vs. the U.S. dollar and a tighter government grip on pharmas to detect malpractices such as rebates - or kickbacks - in the local pharma industry adversely affected the second quarter earnings of LG Life Sciences